Zealand Pharma A/S
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZLDPF | KLRA | ENTX | GPCR | MAZE | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 2.30B | 1.66B | 540.90M | 1.45B | 1.85B | 658.53M |
| P/E (TTM) | 5.7 | — | — | — | — | — |
| Forward P/E | -29.9 | -3.0 | -5.7 | -9.6 | -10.5 | -7.8 |
| Price/book | 0.9 | 0.0 | 21.2 | 1.1 | 4.1 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −53.21% | −50.77% | 0.00% | −39.17% | +12.66% | +3.50% |
| Today | 0.00% | +1.75% | +1.97% | +0.05% | +3.50% | +1.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ZLDPF news ›Royalty Pharma plc and Zealand Pharma A/S Enter into Rusfertide Funding Agreement for $100 Million
Royalty Pharma plc announced an agreement for $100 million in funding to Zealand Pharma A/S in exchange for Zealand Pharma A/S?s economics related to rusfertide , a potential first-in-class therapy... Royalty Pharma plc announced an…
Member Spotlight: Zealand Pharma A/S
Massachusetts Biotechnology Council Zealand Pharma is a biotechnology company transforming metabolic health so millions of people can live without limits. With the opening of its new research hub at 35 CambridgePark Drive, Zealand Pharma…
Zealand Pharma A/S and Generate Biomedicines Inc. Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with Ai for Metabolic Diseases
Zealand Pharma A/S announced a multi-target strategic collaboration with Generate Biomedicines Inc. . Under the collaboration, the companies intend to design and develop multispecific protein... Zealand Pharma A/S announced a multi-target…
Analyzing Zealand Pharma A/S (OTCMKTS:ZLDPF) & Fractyl Health (NASDAQ:GUTS)
Posted by Michael Walen on Oct 14th, 2026 Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) and Fractyl Health (NASDAQ:GUTS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
Zealand Pharma A/S Stock (ZEAL) - Quote Nasdaq Copenhagen
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development…
Zealand Pharma A/S: Relative Strength Chart - Stock Nasdaq Copenhagen
Compare Zealand Pharma A/S with the company of your choice via a Relative Strength chart. Real-time ZEAL price, Nasdaq Copenhagen stock exchange Relative Strength Chart Zealand Pharma A/S Biotechnology & Medical Research All financial news…
Zealand Pharma A/S : Insider Transactions
Follow insider transactions on Zealand Pharma A/S in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Zealand Pharma A/S Biotechnology & Medical Research Latest insider…
Zealand Pharma A/S: Latest Headlines - Nasdaq Copenhagen Stock Exchange
Find the latest highlights on Zealand Pharma A/S at the Nasdaq Copenhagen stock exchange. Highlights Zealand Pharma A/S Biotechnology & Medical Research Zealand Pharma: weight loss fails to carry much weight October 01, 2026 at 07:54 am…
Zealand Pharma A/S: Official Announcements - Stock Market News
Find the latest press releases and official documents published by Zealand Pharma A/S on MarketScreener. Press Releases Zealand Pharma A/S Biotechnology & Medical Research Zealand Pharma: weight loss fails to carry much weight October 01,…
Zealand Pharma A/S Announces Positive Phase 2 ZUPREME-2 Topline Results for Amylin Analog Petrelintide in People with Overweight or Obesity and Type 2 Diabetes
Zealand Pharma A/S announced positive topline results from the Phase 2 ZUPREME-2 trial evaluating the efficacy and safety of petrelintide versus placebo in 220 people living with overweight or obesity...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- massbio.org1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.